ProfoundBio's Rinatabart Sesutecan Granted FDA Fast Track Designation for Ovarian Cancer

Rinatabart sesutecan (Rina-S; PRO1184) is under evaluation for the treatment of patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

Source link
#ProfoundBio039s #Rinatabart #Sesutecan #Granted #FDA #Fast #Track #Designation #Ovarian #Cancer